New Targets in Non-Small Cell Lung Cancer.
With the implementation of genomic technologies into clinical practice, we have examples of the predictive benefit of targeted therapy for oncogene-addicted cancer and identified molecular dependencies in non-small cell lung cancer. The clinical success of tyrosine kinase inhibitors against epidermal growth factor receptor and anaplastic lymphoma kinase activation has shifted treatment emphasize the separation of subsets of lung cancer and genotype-directed therapy. Advances have validated oncogenic driver genes and led to the development of targeted agents. This review highlights treatment options, including clinical trials for ROS1 rearrangement, RET fusions, NTRK1 fusions, MET exon skipping, BRAF mutations, and KRAS mutations.
['Park|Soo J|SJ|', 'More|Soham|S|', 'Murtuza|Ayesha|A|', 'Woodward|Brian D|BD|', 'Husain|Hatim|H|']
D000970:Antineoplastic Agents D002289:Carcinoma, Non-Small-Cell Lung D016503:Drug Delivery Systems D006801:Humans D008175:Lung Neoplasms D009154:Mutation D009363:Neoplasm Proteins
ROS1 RET MET BRAF KRAS Driver mutations NSCLC NTRK